June 10, 2025

Recent Advances in Treating Diffuse Large B-Cell Lymphoma

The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma and included both lymphomas...

The ASCO Post

June 10, 2025

Castor Oil

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. ...

The ASCO Post

June 03, 2025

Niraparib Plus Abiraterone in HRR-Mutant Metastatic Castration-Sensitive Prostate Cancer

Results from the international phase III AMPLITUDE trial found that adding niraparib to abiraterone acetate plus prednisone significantly improved radiographic progression–free survival compared with ...

The ASCO Post

May 28, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

May 28, 2025

Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD

Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual ...

The ASCO Post

May 23, 2025

The Legal Impacts on Oncology Care of Prohibiting Diversity, Equity, and Inclusion Efforts

In January 2025, the Trump Administration issued executive orders asserting opposition to diversity, equity, and inclusion (DEI) programs on the federal level and rescinding Biden Administration order...

The ASCO Post

May 22, 2025

Combination Therapy for Newly Diagnosed, BRCA-Nonmutated, Advanced Epithelial Ovarian Cancer

The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inh...

The ASCO Post

May 20, 2025

A High Proportion of U.S. Adults Are Behind on Cancer Screenings

A new survey conducted by the American Cancer Society Cancer Action Network found that over one-third of U.S. adults are more than 1 year behind on their cancer screenings.

The ASCO Post

May 16, 2025

Retifanlimab-dlwr Approved for Anal Cancer

The FDA approved the PD-1–blocking monoclonal antibody in combination with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous ce...

The ASCO Post